Back
Aligos Therapeutics, Inc. 10K Form
Sell
27
ALGS
Aligos Therapeutics, Inc.
Last Price:
$7.00
Seasonality Move:
-25.49%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive ALGS News And Ratings
See the #1 stock for the next 7 days that we like better than ALGS
ALGS Financial Statistics
Sales & Book Value
| Annual Sales: | $2.2M |
|---|---|
| Cash Flow: | $-21.8M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $8.67 |
| Price / Book: | 0.81 |
Profitability
| EPS (TTM): | -8.60170 |
|---|---|
| Net Income (TTM): | $-24.2M |
| Gross Margin: | $1.3M |
| Return on Equity: | -38.44% |
| Return on Assets: | -21.73% |
Aligos Therapeutics, Inc. Earnings Forecast
Key Aligos Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 8 years for ALGS is 57.46%.
-
The Selling, General & Administrative Expenses for ALGS have been equal to 947.76% of Gross Profit Margin.
-
The Research & Development expenses have been 3,177.17% of Revenue.
-
The Net Earning history of ALGS is -1,106.72% of Total Revenues.
-
Per Share Earnings over the last 8 years have been positive in 2 years.
Aligos Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ALGS |
| Website: | aligos.com |
Debt
| Debt-to-Equity Ratio: | 0.1 |
|---|---|
| Current Ratio: | 3.9 |
| Quick Ratio: | 3.67 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ALGS Technical Analysis vs Fundamental Analysis
Sell
27
Aligos Therapeutics, Inc. (ALGS)
is a Sell
Is Aligos Therapeutics, Inc. a Buy or a Sell?
-
Aligos Therapeutics, Inc. stock is rated a SellThe current Aligos Therapeutics, Inc. [ALGS] share price is $7.03. The Score for ALGS is 27, which is 46% below its historic median score of 50, and infers higher risk than normal.